Cialis shows promise as prostate cancer treatment

Share this article:
Lilly ICOS said its erectile dysfunction (ED) drug Cialis has shown promise in easing urinary problems from benign enlargement of the prostate in men.
A Phase II study showed "statistically significant improvement" in male patients with the prostate problem, a condition known as benign prostatic hyperplasia (BPH).
The trial lasted 12 weeks and consisted of asking an unspecified number of participants to fill out a seven-item questionnaire to assess the severity of symptoms of BPH and the response to therapy.
Lilly may be hoping to find new indication-related success similar to that experienced by Cialis competitor Viagra, which was granted FDA approval for a new indication under a different name earlier this year. Pfizer's Viagra was re-branded as Revatio to treat pulmonary hypertension, a rare, potentially fatal lung disease, in June.
For the first quarter of 2005, Cialis' share of the U.S. ED market was 21.1 percent, compared with 10.4 percent for Levitra and 65 percent for Viagra, according to IMS Health data.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.